Mathieu Simon
Chairman at IDORSIA LTD
Net worth: 263 805 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jean-Marie Messier | M | 68 |
Messier Maris & Associés SCA
 Messier Maris & Associés SCA Investment ManagersFinance Messier Maris & Associés SCA provides financial consulting and investment advisory services. The company was founded by Jean-Marie Messier and Erik Maris in 2010 and is headquartered in Paris, France. | 14 years |
| Harry Welten | M | 59 |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 4 years |
| Adolf Hoess | M | 62 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 14 years |
| Jean-Paul Clozel | M | 69 |
Idorsia Pharmaceuticals Ltd.
 Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 7 years |
| André Muller | M | 60 |
Pierre Fabre SA
 Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France.
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 25 years |
| Thomas O. Hecht | M | 73 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 17 years |
| Ferdinand Verdonck | M | 81 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 10 years |
| Bernhard R. M. Ehmer | M | 69 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 8 years |
| Ulrich Grau | M | 75 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 9 years |
| Annalisa Jenkins | M | 58 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 4 years |
| Rainer Boehm | M | 63 | 7 years | |
| Sonia Longo Sormani | M | - |
Aileens Pharma Srl
 Aileens Pharma Srl Miscellaneous Commercial ServicesCommercial Services Aileens Pharma Srl is a holding company, which engages in the research and development of treatments for dermatological diseases. The company was founded by Sonia Longo Sormani in 2018 and is headquartered in Nova Milanese, Italy. | 6 years |
| Peter Kellogg | M | 67 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 3 years |
| Srishti Gupta | M | 48 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 3 years |
| Julien Gander | M | 45 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | - |
| Uta Kemmerich-Keil | F | 58 | 3 years | |
| Andreas Harstrick | M | 63 | 4 years | |
| Mary Beth Sandin | F | - | - | |
| Sandy Mahatme | M | 59 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 4 years |
| Constanze Ulmer-Eilfort | M | 62 | 1 years | |
| Felix R. Ehrat | M | 67 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 4 years |
| Andrew C. Weiss | M | 55 | 7 years | |
| Jörn Aldag | M | 65 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 4 years |
| Wolfgang Fischer | M | 60 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 7 years |
| Sophie Kornowski-Bonnet | M | 61 | 1 years | |
| Paola Pozzi | F | - |
Epsilen Bio Srl
 Epsilen Bio Srl Pharmaceuticals: MajorHealth Technology Epsilen Bio SRL operates as a biotechnology company. It develops novel therapies based on epigenetic silencing. The company was founded by Angelo Lombardo and Luigi Naldini in December 2019 and is headquartered in Milan, Italy. | - |
| Luca G. Guidotti | M | 63 |
Epsilen Bio Srl
Epsilen Bio Srl Pharmaceuticals: MajorHealth Technology Epsilen Bio SRL operates as a biotechnology company. It develops novel therapies based on epigenetic silencing. The company was founded by Angelo Lombardo and Luigi Naldini in December 2019 and is headquartered in Milan, Italy. | - |
| Maurizio Comini | M | - |
Aileens Pharma Srl
Aileens Pharma Srl Miscellaneous Commercial ServicesCommercial Services Aileens Pharma Srl is a holding company, which engages in the research and development of treatments for dermatological diseases. The company was founded by Sonia Longo Sormani in 2018 and is headquartered in Nova Milanese, Italy. | - |
| Francesca Pasinelli | F | 64 |
Epsilen Bio Srl
Epsilen Bio Srl Pharmaceuticals: MajorHealth Technology Epsilen Bio SRL operates as a biotechnology company. It develops novel therapies based on epigenetic silencing. The company was founded by Angelo Lombardo and Luigi Naldini in December 2019 and is headquartered in Milan, Italy. | - |
| Denise Mueller | F | 55 | 8 years | |
| Alexander Fudukidis | M | - | 4 years | |
| Alexander Khatuntsev | M | 45 | 7 years | |
| Svetlana Vashkel | F | - |
Aileens Pharma Srl
Aileens Pharma Srl Miscellaneous Commercial ServicesCommercial Services Aileens Pharma Srl is a holding company, which engages in the research and development of treatments for dermatological diseases. The company was founded by Sonia Longo Sormani in 2018 and is headquartered in Nova Milanese, Italy. | - |
| Julia Berretta | M | 43 |
Epsilen Bio Srl
Epsilen Bio Srl Pharmaceuticals: MajorHealth Technology Epsilen Bio SRL operates as a biotechnology company. It develops novel therapies based on epigenetic silencing. The company was founded by Angelo Lombardo and Luigi Naldini in December 2019 and is headquartered in Milan, Italy. | - |
| Susanne Hering | F | - | 9 years | |
| Barbara Castellano | F | - |
Aileens Pharma Srl
Aileens Pharma Srl Miscellaneous Commercial ServicesCommercial Services Aileens Pharma Srl is a holding company, which engages in the research and development of treatments for dermatological diseases. The company was founded by Sonia Longo Sormani in 2018 and is headquartered in Nova Milanese, Italy. | - |
| Simon Jose | M | 58 | 6 years | |
| Martine Clozel | M | 68 | 7 years | |
| Alberto Gimona | M | 64 | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Simon Harnest | M | 37 | 6 years | |
| Jean-Pierre Garnier | M | 75 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017.
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | 6 years |
| Marc Le Bozec | M | - | 7 years | |
| Berndt A. E. Modig | M | 65 | 6 years | |
| Olivier Jean Bohuon | M | 65 |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | 1 years |
| David Sourdive | M | 57 |
Ectycell SASU
 Ectycell SASU BiotechnologyHealth Technology Ectycell SASU produces and sales stem cells. It offers pluripotent stem cells that can be used to develop drugs and model diseases. The company was founded in September 2009 and is headquartered in Romainville, France. | 3 years |
| Elsy Boglioli Hofman | F | 42 | 2 years | |
| Herve Hoppenot | M | 64 | 6 years | |
| Florian Fischer | M | 56 | 15 years | |
| Bernard Poussot | M | 72 |
Wyeth-Ayerst International LLC
| 6 years |
| Thierry Moulin | M | - | - | |
| Stephane Depil | M | 50 | 2 years | |
| Angus Smith | M | 41 | 3 years | |
| Viviane Monges | F | 60 | 3 years | |
| Eric Dutang | M | 50 | - | |
| Leila Alland | M | 61 | 1 years | |
| Loan Hoang-Sayag | M | 57 | 1 years | |
| John Greisch | M | 68 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 3 years |
| Frédéric Cédrone | M | - | - | |
| Frédéric Duchesne | M | 64 |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | 9 years |
| Stephan Reynier | M | 55 |
Ectycell SASU
Ectycell SASU BiotechnologyHealth Technology Ectycell SASU produces and sales stem cells. It offers pluripotent stem cells that can be used to develop drugs and model diseases. The company was founded in September 2009 and is headquartered in Romainville, France. | 3 years |
| Oliver Bohoun | M | 65 |
Pierre Fabre SA
Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | - |
| Arndt Justus Georg Schottelius | M | 58 | 4 years | |
| Martin Treder | M | - | 4 years | |
| Michael Fare | M | - |
Wyeth-Ayerst International LLC
| 11 years |
| Frédéric Pâques | M | - | 11 years | |
| Michel de Rosen | M | 73 | 1 years | |
| Guy Braunstein | M | 67 | 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Germany | 21 | 31.34% |
| France | 19 | 28.36% |
| Switzerland | 19 | 28.36% |
| Italy | 8 | 11.94% |
| United States | 2 | 2.99% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mathieu Simon
- Personal Network